Vanda Pharmaceuticals Reports Third-Quarter 2026 Revenue of $69.82M
Revenue rose 24.1% year over year to $69.82 million. Net loss was $22.56 million versus $22.59 million a year earlier; diluted loss per share was $0.37 versus $0.38.
Vanda Pharmaceuticals reported third-quarter 2026 revenue of $69.82 million, up 24.1% year over year. Net loss was $22.56 million, compared with $22.59 million in the prior-year quarter, while diluted loss per share was $0.37 versus $0.38.Financial Highlights¹ Reported as “Total revenues”. ² Report…